Actualización de tratamiento farmacológico de enfermedad Renal en pacientes diabéticos.
DOI:
https://doi.org/10.56048/MQR20225.7.3.2023.3494-3515Palabras clave:
diabetes, enfermedad renal, fatores de riesgo, nefropatía, tratamiento actualizado.Resumen
Antecedentes: se menciona en la federación internacional de la diabetes que aproximadamente 537 millones de adultos desde los 20 a los 79 años, padecen diabetes mellitus el año 2021, se estima que este número se incremente a 780 millones para el año 2045. Además, se menciona que el 90% y 95% de todos estos pacientes tienen diabetes mellitus tipo 2, sumando a esto se observa que en la mitad de esta población desarrollarla enfermedad renal diabética o nefropatía diabética Objetivo: detallar el tratamiento actualizado de la nefropatía diabética. Metodología: se realizará una revisión bibliográfica tipo narrativa, que incluyan artículos científicos sobre la terapia biológica y moduladores del sistema inmunológico en LA Actualización de tratamiento farmacológico de enfermedad renal en pacientes diabéticos, recogidos de diferentes bases de datos como PUBMED, Medline, Scielo y Elseiver, Scopus, mediante identificación-cribado-elegibilidad-selección y basado en el rango de calidad de Scimago Journal Rank. Resultados esperados: mediante una búsqueda exhaustiva de documentos científicos, se pretende condensar información con relevancia clínica sobre la actualización de tratamiento farmacológico de enfermedad renal en pacientes diabéticos.
Descargas
Métricas
Cited
DOI: 10.56048
Citas
Wheeler DC, Stefánsson B V., Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. lancet Diabetes Endocrinol [Internet]. 2021 Jan 1 [cited 2023 Jul 14];9(1):22–31. Available from: https://pubmed.ncbi.nlm.nih.gov/33338413/
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 May 11;393(10184):1937–47.
Wu T, Ding L, Andoh V, Zhang J, Chen L. The Mechanism of Hyperglycemia-Induced Renal Cell Injury in Diabetic Nephropathy Disease: An Update. Life (Basel). 2023 Feb 15;13(2):539.
Naaman SC, Bakris GL. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care. 2023 Sep 1;46(9):1574-1586.
Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2019;(3).
Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.Cardiovasc Diabetol [Internet]. 2021 Dec 1 [cited 2023 Jul 14];20(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33413348/
Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, et al. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation [Internet]. 2022 Feb 8 [cited 2023 Jul 14];145(6):437–47. Available from: https://pubmed.ncbi.nlm.nih.gov/34775784/
Pozo Garcia L, Thomas SS, Rajesh H, Navaneethan SD. Progress in the management of patients with diabetes and chronic kidney disease. Curr Opin Nephrol Hypertens [Internet]. 2022 Sep 1 [cited 2023 Jul 14];31(5):456–63. Available from: https://pubmed.ncbi.nlm.nih.gov/35894280/
Mende CW. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape [Internet]. Vol. 39, Advances in Therapy. Adv Ther; 2022 [cited 2023 Jul 14]. p. 148–64. Available from: https://pubmed.ncbi.nlm.nih.gov/34846711/
Gómez-Huelgas R, Martínez-Castelao A, Artola S, Górriz JL, Menéndez E. Tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. Med Clin (Barc) [Internet]. 2014 Jan 21 [cited 2023 Jul 14];142(2):85.e1-85.e10. Available from: https://www.elsevier.es/es-revista-medicina-clinica-2-articulo-tratamiento- diabetes-tipo-2-el-S0025775313007495
Agarwal R, Anker SD, Bakris G, Filippatos G, Pitt B, Rossing P, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant [Internet]. 2022 Jun 1 [cited 2023 Jul 14];37(6):1014–23. Available from: https://pubmed.ncbi.nlm.nih.gov/33280027/
Kelly MS, Lewis J, Huntsberry AM, Dea L, Portillo I. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgrad Med [Internet]. 2019 Jan 2 [cited 2023 Jul 14];131(1):31–42. Available from: https://pubmed.ncbi.nlm.nih.gov/30449220/
Forst T, Mathieu C, Giorgino F, Wheeler DC, Papanas N, Schmieder RE, Halabi A, Schnell O, Streckbein M, Tuttle KR. New strategies to improve clinical outcomes for diabetic kidney disease. BMC Med. 2022 Oct 10;20(1):337.
Sagoo MK, Gnudi L. Diabetic Nephropathy: An Overview. Methods Mol Biol. 2020;2067:37.
Xiong Y, Zhou L. The Signaling of Cellular Senescence in Diabetic Nephropathy. Oxid Med Cell Longev. 2019 Oct 3;2019:7495629.
Samsu N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. Biomed Res Int. 2021 Jul 8;2021:1497449.
Li S, Zheng L, Zhang J, Liu X, Wu Z. Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathy. Free Radic Biol Med. 2021 Jan;162:435-449.
Thipsawat S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature. Diab Vasc Dis Res. 2021 Nov-Dec;18(6):14791641211058856.
Pereira PR, Carrageta DF, Oliveira PF, Rodrigues A, Alves MG, Monteiro MP. Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease. Med Res Rev. 2022 Jul;42(4):1518-1544.
de Bhailís ÁM, Azmi S, Kalra PA. Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes. Ther Adv Endocrinol Metab. 2021 May 29;12:20420188211020664.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229.
Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodiumglucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:422-34.
Ruilope LM, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol 2019;50: 345-56.
Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int 2019;96:302-19.
Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020 Apr;22 Suppl 1:3-15.
Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, Filippatos G, Pitt B, Rossing P, Lambelet M, Nowack C, Kolkhof P, Joseph A, Bakris GL. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023 Feb 1;41(2):295-302.
Forst T, Mathieu C, Giorgino F, Wheeler DC, Papanas N, Schmieder RE, Halabi A, Schnell O, Streckbein M, Tuttle KR. New strategies to improve clinical outcomes for diabetic kidney disease. BMC Med. 2022 Oct 10;20(1):337.
Song A, Zhang C, Meng X. Mechanism and application of metformin in kidney diseases: An update. Biomed Pharmacother. 2021 Jun;138:111454.
Wish JB, Pergola P. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus. Mayo Clin Proc Innov Qual Outcomes. 2022 Oct 15;6(6):536-551.
Correa-Rotter R, Rosas-Guzmán J, Méndez-Durán A, Sebastián-Díaz MA, Díaz-Avendaño ODC, Mehta-Pravin R, Alcocer-Gamba MA. Documento de consenso sobre el uso de iSGLT2 en pacientes con enfermedad renal crónica y diabetes. Gac Med Mex. 2022;158(M2):M1-M12. English
Varghese RT, Jialal I. Diabetic Nephropathy. 2022 Jul 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.
Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Julious S, Rajbhandari S, Sharma S, Rayman G, Gouni R, Alam U, Cooper C, Loban A, Sutherland K, Glover R, Waterhouse S, Turton E, Horspool M, Gandhi R, Maguire D, Jude EB, Ahmed SH, Vas P, Hariman C, McDougall C, Devers M, Tsatlidis V, Johnson M, Rice ASC, Bouhassira D, Bennett DL, Selvarajah D; OPTION-DM trial group. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet. 2022 Aug 27;400(10353):680-690.
Zuo Y, Li T, Lei Z. Should we add atorvastatin to irbesartan for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials. Pharmacol Res. 2019 Aug;146:104286.
Lu Y, Liu D, Feng Q, Liu Z. Diabetic Nephropathy: Perspective on Extracellular Vesicles. Front Immunol. 2020 Jun 3;11:943.
Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020;63:221-228.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-2306.
Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int 2019;96:302-319.
Grune J, Beyhoff N, Smeir E, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone’s antifibrotic activity. Hypertension 2018;71:599-608.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229.
Georgianos PI, Vaios V, Eleftheriadis T, Papachristou E, Liakopoulos V. Therapeutic Advances in Diabetic Kidney Disease. Int J Mol Sci. 2023 Feb 1;24(3):2803.
Bhatt D.L., Szarek M., Pitt B., Cannon C.P., Leiter L.A., McGuire D.K., Lewis J.B., Riddle M.C., Inzucchi S.E., Kosiborod M.N., et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N. Engl. J. Med. 2021;384:129–139.
Lee JY, Yang JW, Han BG, Choi SO, Kim JS. Adiponectin for the treatment of diabetic nephropathy. Korean J Intern Med. 2019 May;34(3):480-491.
Esparragoza, J. P., Muñoz, R. J., Boldoba, N. B., & del Valle, K. P. (2023). Protocolo de tratamiento de la nefropatía diabética. Medicine-Programa de Formación Médica Continuada Acreditado, 13(79), 4708-4713.
George C, Echouffo-Tcheugui JB, Jaar BG, Okpechi IG, Kengne AP. The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low-and-middle income countries-a review of the current literature. BMC Med. 2022;20(1):247.
Hassanein M, Shafi T. Assessment of glycemia in chronic kidney disease. BMC Med. 2022;20(1):117.
Yamazaki T, Mimura I, Tanaka T, Nangaku M. Treatment of Diabetic Kidney Disease: Current and Future. Diabetes Metab J. 2021 Jan;45(1):11-26.
Ito M, Tanaka T, Nangaku M. Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases. Curr Opin Nephrol Hypertens. 2020;29:128–35.
Hanouneh M, EchouffoTcheugui JB, Jaar BG. Recent advances in diabetic kidney disease. BMC Med. 2021;19(1):180.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229.
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 MQRInvestigar
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores se comprometen a respetar la información académica de otros autores, y a ceder los derechos de autor a la Revista MQRInvestigar, para que el artículo pueda ser editado, publicado y distribuido. El contenido de los artículos científicos y de las publicaciones que aparecen en la revista es responsabilidad exclusiva de sus autores. La distribución de los artículos publicados se realiza bajo una licencia